Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
BERKELEY, Calif., Feb. 03, 2016 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, was invited to present at the 5th Annual Leerink Partners Global Healthcare Conference in New York, NY on Wednesday, February 10, 2016, at 8:25 am Eastern Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's cyclic dinucleotide (CDN) platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Angela Bitting 925 202 6211 [email protected] Mike Beyer Sam Brown, Inc. 312 961 2502
